SANGAMO REPORTS SB-509 TRIAL DATA

A A

Sangamo BioSciences has announced that a Phase I human clinical trial of SB-509 or ZFP Therapeutic for the treatment of diabetic neuropathy appears to be safe and well-tolerated.

The SB-509 is an injectable formulation of plasmid DNA that encodes a zinc finger DNA binding protein transcriptase factor. The dose-escalation study results were presented recently at the 58th Annual Meeting of the American Academy of Neurology in San Diego.